Thursday, September 17, 2026
21.3 C
Bengaluru

Indian Hospitals and Private Equity: Healthy for Patients?

If healthcare is so lucrative that global private equity firms are willing to write cheques of Rs 13,000–14,000 crore for a single mid-sized Indian hospital chain, why is the Indian government still reluctant to invest at scale?

Public health expenditure in India remains stubbornly low — around 1.4–1.8 per cent of GDP in recent National Health Accounts estimates, far short of the National Health Policy 2017 target of 2.5 per cent by 2025. The Centre’s own allocation hovers near 0.26–0.28 per cent of GDP.

States carry the bulk of the burden, yet the combined public effort has never matched the rhetoric of “health as a right.” Fiscal constraints, competing demands (defence, infrastructure, subsidies), and the political economy of short-term welfare schemes over long-term capacity building explain part of the story. The deeper issue is that governments prefer to underwrite demand (through insurance schemes like Ayushman Bharat) rather than own and operate supply at the scale private capital is now willing to fund.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Topics

Medical Reps—Lessons From The West: The Old Model is Dead

The Core Conclusion The Western pharma industry is not simply...

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...
spot_img

Related Articles

spot_imgspot_img